THE IMMUNOREACTIVE GROWTH HORMONE IN SERUM FROM PATIENTS WITH VARIOUS TYPES OF DIABETES MELLITUS

1970 ◽  
Vol 64 (2) ◽  
pp. 339-346 ◽  
Author(s):  
Hans Yde
Keyword(s):  
Growth Hormone ◽  
Oral Glucose ◽  
Newly Diagnosed ◽  
Significant Elevation ◽  
Fasting Serum ◽  
Serum Growth Hormone ◽  
Order Of Magnitude ◽  
Juvenile Diabetics ◽  
The Mean

ABSTRACT Employing a chromatographic method the immuno-reactive serum growth hormone was determined in 102 diabetics and 45 controls. The diabetic group consisted of 40 juvenile diabetics and 62 newly diagnosed untreated maturity-onset diabetics. 12 of the juvenile diabetics were newly diagnosed and untreated, while the remaining 28 were long-term diabetics. 33 of the maturity-onset diabetics were non-obese while 29 were obese. All the persons were investigated while fasting in the resting state before getting out of bed. All the groups of diabetics presented an elevated mean fasting serum growth hormone of the same order of magnitude. When the total group of 102 diabetics was analysed against the controls, and also when the 62 maturity-onset diabetics were analysed separately, a statistically significant elevation in the mean fasting serum growth hormone was obtained. This was not the case when the group of 40 juvenile diabetics were analysed separately. In 10 maturity-onset diabetics the serum growth hormone response to oral glucose was found to be normal as compared to 13 controls.

IMMUNOREACTIVE GROWTH HORMONE IN PLASMA AND URINE IN JUVENILE DIABETICS BEFORE AND DURING INITIAL INSULIN TREATMENT

1974 ◽  
Vol 75 (1) ◽  
pp. 50-63 ◽  
Author(s):  
Kristian F. Hanssen
Keyword(s):  
Growth Hormone ◽  
Insulin Treatment ◽  
Juvenile Diabetes ◽  
Control Group ◽  
List Type ◽  
Newly Diagnosed ◽  
Renal Tubular Reabsorption ◽  
Juvenile Diabetics ◽  
The Mean ◽  
Renal Tubular

ABSTRACT Twenty newly diagnosed, but as yet untreated patients of both sexes with classical juvenile diabetes were investigated by determining the mean plasma immunoreactive growth hormone (IRHGH) and urinary IRHGH for a 24 hour period before and during initial insulin treatment. The plasma IRHGH was significantly higher (0.05 > P > 0.01) before than during initial insulin treatment. During initial insulin treatment, the mean plasma IRHGH was significantly higher (0.01 > P > 0.001) than in a control group. The urinary IRHGH was significantly higher (0.01 > P > 0.001) before than during insulin treatment. The increased urinary IRHGH observed before insulin treatment is thought to be partly due to a defective renal tubular reabsorption of growth hormone. No significant correlation was found between the mean blood sugar and plasma or urinary IRHGH either before or during insulin treatment.

SERUM GROWTH HORMONE RESPONSF TO BROMOCRIPTINE DURING A GLUCOSE TOLERANCE TEST IN ACROMEGALY

1976 ◽  
Vol 82 (1) ◽  
pp. 39-46 ◽  
Author(s):  
J. Cassar ◽  
K. Mashiter ◽  
G. Sullivan ◽  
G. F. Joplin
Keyword(s):  
Growth Hormone ◽  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Term Treatment ◽  
Distinct Pattern ◽  
Oral Glucose ◽  
Serum Growth Hormone ◽  
Long Term Treatment

ABSTRACT Serum growth hormone was assayed in eighteen acromegalic patients during an oral glucose tolerance test with and without 2.5 mg bromocriptine. The serum growth hormone levels during the glucose tolerance test with bromocriptine, although significantly lower at two sampling times, do not show any distinct pattern. We conclude that such an acute test will not distinguish the patient who might respond to long term treatment with bromocriptine.

Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients

1993 ◽  
Vol 129 (3) ◽  
pp. 207-212 ◽  
Author(s):  
Yi-Fan Shi ◽  
Xian-Feng Zhu ◽  
Alan G Harris ◽  
Jin-Xi Zhang ◽  
Jie-Ying Deng
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Term Therapy ◽  
Serum Growth Hormone ◽  
Factor I ◽  
Gallbladder Contractility ◽  
Octreotide Therapy ◽  
Long Term Therapy ◽  
Growth Hormone Suppression

We sought to examine how the discontinuation of octreotide in long-term octreotide-treated acromegalic patients affects the well-documented side-effect of cholelithiasis. In 14 acromegalic patients, serum growth hormone levels, insulin-like growth factor I levels and percentage of relative gallbladder contractility were measured prior to and after the discontinuation of octreotide. Compared to pretreatment values, the basal growth hormone and 5-h growth hormone profiles were 36% and 24%, and 60% and 56% at the end of 1 and 2 weeks, respectively. Octreotide was found to be eliminated completely from the serum within 3 days after its withdrawal. In all of six patients who did not develop gallstones, the percentage relative gallbladder contractility normalized within 1 week. In eight patients who developed gallstones, four of them had restoration of normal contractility within 2 weeks. Our results show that upon withdrawal of octreotide, gallbladder contractility returns to normal while growth hormone suppression persists for a longer period of time. Therefore, discontinuation of octreotide therapy may allow for the clearance of stagnated bile and hence decrease the incidence of cholelithiasis in acromegalic patients receiving long-term therapy.

Long-term results of gamma knife surgery for growth hormone—producing pituitary adenoma: is the disease difficult to cure?

2005 ◽  
Vol 102 (Special_Supplement) ◽  
pp. 119-123 ◽  
Author(s):  
Tatsuya Kobayashi ◽  
Yoshimasa Mori ◽  
Yukio Uchiyama ◽  
Yoshihisa Kida ◽  
Shigeru Fujitani
Keyword(s):  
Growth Hormone ◽  
Gamma Knife ◽  
Pituitary Adenomas ◽  
Gamma Knife Surgery ◽  
Long Term Results ◽  
Content Type ◽  
The Mean ◽  
Dose Radiation ◽  
Fine Print

Object. The authors conducted a study to determine the long-term results of gamma knife surgery for residual or recurrent growth hormine (GH)—producing pituitary adenomas and to compare the results with those after treatment of other pituitary adenomas. Methods. The series consisted of 67 patients. The mean tumor diameter was 19.2 mm and volume was 5.4 cm3. The mean maximum dose was 35.3 Gy and the mean margin dose was 18.9 Gy. The mean follow-up duration was 63.3 months (range 13–142 months). The tumor resolution rate was 2%, the response rate 68.3%, and the control rate 100%. Growth hormone normalization (GH < 1.0 ng/ml) was found in 4.8%, nearly normal (< 2.0 ng/ml) in 11.9%, significantly decreased (< 5.0 ng/ml) in 23.8%, decreased in 21.4%, unchanged in 21.4%, and increased in 16.7%. Serum insulin-like growth factor (IGF)—1 was significantly decreased (IGF-1 < 400 ng/ml) in 40.7%, decreased in 29.6%, unchanged in 18.5%, and increased in 11.1%, which was almost parallel to the GH changes. Conclusions. Gamma knife surgery was effective and safe for the control of tumors; however, normalization of GH and IGF-1 secretion was difficult to achieve in cases with large tumors and low-dose radiation. Gamma knife radiosurgery is thus indicated for small tumors after surgery or medication therapy when a relatively high-dose radiation is required.

Long-term Changes in Serum IGF-1 Levels After Successful Surgical Treatment of Growth Hormone–Secreting Pituitary Adenoma

Neurosurgery ◽  
2013 ◽  
Vol 73 (3) ◽  
pp. 473-479 ◽  
Author(s):  
Mi-Seon Shin ◽  
Ji Hee Yu ◽  
Jong Han Choi ◽  
Chang Hee Jung ◽  
Jenie Yoonoo Hwang ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Growth Hormone ◽  
Surgical Treatment ◽  
Magnetic Resonance ◽  
Serum Insulin ◽  
Tumor Resection ◽  
Oral Glucose ◽  
Resonance Imaging ◽  
Long Term Changes

Abstract BACKGROUND: Successful treatment of acromegaly is known to normalize serum insulin-like growth factor 1 (IGF-1) levels within days after surgery. However, our clinical observations indicate that many cases of acromegaly show delayed normalization of serum IGF-1 levels after complete tumor resection. OBJECTIVE: To study long-term changes of the serum IGF-1 levels in acromegalic patients for whom surgical treatment was thought to be successful. METHODS: A retrospective observational study was performed with 46 acromegalic patients with no residual tumor on sellar magnetic resonance imaging, and a nadir growth hormone of less than 0.4 μg/L on a postoperative oral glucose tolerance test. RESULTS: In all patients, serum IGF-1 levels returned to the normal reference values for age and sex during the observational period (12-132 months). The mean duration from the time of surgery until IGF-1 normalization was 10 months (range, 3 days-57 months). Twenty-seven patients (59%) reached normal IGF-1 ranges within 3 months of surgery, whereas 19 patients (41%) experienced delayed (&gt;3 months) IGF-1 normalization. Eleven patients (24%) recovered normal IGF-1 levels 12 to 57 months after surgery. The possibility of delayed IGF-1 cure was increased 8.8-fold with an immediate postoperative IGF-1 level increase of 100 μg/L. CONCLUSION: Satisfactory remission of acromegaly by IGF-1 criteria was delayed in a large proportion of acromegalic patients, especially those with high postoperative IGF-1 levels. Hence, additional treatment can be delayed in clinically stable acromegalic patients who show no evidence of residual tumors on postoperative magnetic resonance imaging and a normal growth hormone suppressive response to a glucose load.

Efficacy of cryohypophysectomy in the treatment of acromegaly

1977 ◽  
Vol 46 (1) ◽  
pp. 1-11 ◽  
Author(s):  
Michael V. DiTullio ◽  
Robert W. Rand
Keyword(s):  
Growth Hormone ◽  
Glucose Tolerance ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Serum Growth Hormone ◽  
Beneficial Result ◽  
Content Type ◽  
Glucose Tolerance Curve ◽  
Tolerance Curve ◽  
Suprasellar Extension

✓ Between 1963 and 1974, 54 patients with acromegaly (28 men and 26 women) ranging in age from 23 to 61 years were evaluated. Each patient underwent thorough preoperative neurological, roentgenographic, and endocrinological surveys; most demonstrated mild-to-severe abnormalities in growth hormone immunoassay and oral glucose tolerance. Of those who underwent stereotaxic cryohypophysectomy, approximately 80% were considered to have a beneficial result. The efficacy of this form of therapy was judged on the basis of: 1) significant overall clinical improvement and regression of acromegalic features; 2) improvement in the glucose tolerance curve; and 3) a fall of serum growth hormone below 10 ng/ml. Complications including rhinorrhea, meningitis, and hemorrhage occurred in only a small number of cases. A comparison is made between this technique and others, including craniotomy, radiotherapy, and transnasal transsphenoidal hypophysectomy. The efficacy, low morbidity, and the ease with which the procedure may be performed make this our treatment of choice when dealing with growth-hormone-producing pituitary adenomas with no suprasellar extension.

Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children

1996 ◽  
Vol 134 (6) ◽  
pp. 716-719 ◽  
Author(s):  
Beatrice Klinger ◽  
Aviva Silbergeld ◽  
Romano Deghenghi ◽  
Jenny Frenkel ◽  
Zvi Laron
Keyword(s):  
Growth Hormone ◽  
Growth Velocity ◽  
Biological Effects ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Human Growth ◽  
Pediatric Endocrinology ◽  
Short Children ◽  
The Mean

Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormonereleasing peptide in short children. Eur J Endocrinol 1996;134:716–9. ISSN 0804–4643 A clinical, prospective experiment was carried out to determine whether long-term intranasal administration of the growth hormone-releasing peptide hexarelin (His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2) affects pituitary growth hormone secretion. Hexarelin (60 μg/kg t.i.d.) was administered to seven prepubertal constitutionally short children (mean age ±sd = 7.6 ± 2.4 years). Serum human growth hormone (hGH) response to an intranasal (20 μg/kg) and intravenous (1 μg/kg) bolus of hexarelin before, during and after 6–10 months of treatment was measured. The mean (±sd) peak rise of hGH to the intranasal bolus before treatment was 70.6 ± mU/I. After 7 days of hexarelin treatment, mean peak values dropped to 34.1 ±15.7 mU/l (p < 0.002) and thereafter remained constant for 6 months of treatment at 37.5 10.3 ±mU/l (p < 0.03). The pretreatment peak to the iv hexarelin bolus was 84.8 52.5 ±mU/l, and at the end of the treatment period it was 19.8 10.9 ±mU/l (p < 0.05). Three months after stopping treatment the mean (±sd) hGH response rose to 42.1 ±4.7 mU/l (p < 0.005). Growth velocity increased from 5.3±0.9 cm/year (before treatment) to 7.4 1.6 cm/year at ±6–10 months of treatment (p < 0.005). In conclusion, the partial suppression of pituitary hGH responsiveness to long-term intranasal hexarelin treatment, probably due to desensitization, does not affect the observed increase in growth velocity. Z Laron, Pediatric Endocrinology, 11 El Al Street, Ramat Efal, 52960, Israel

Sign in / Sign up

Export Citation Format

Share Document